Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Growth in Short Interest

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant growth in short interest in the month of February. As of February 27th, there was short interest totaling 37,152 shares, a growth of 48.6% from the February 12th total of 24,997 shares. Based on an average trading volume of 810,829 shares, the short-interest ratio is presently 0.0 days. Approximately 5.2% of the shares of the stock are short sold. Approximately 5.2% of the shares of the stock are short sold. Based on an average trading volume of 810,829 shares, the short-interest ratio is presently 0.0 days.

Institutional Trading of Bluejay Diagnostics

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors.

Bluejay Diagnostics Trading Down 4.0%

NASDAQ:BJDX opened at $1.90 on Friday. The stock has a market capitalization of $1.84 million, a P/E ratio of 0.00 and a beta of 0.72. Bluejay Diagnostics has a 1 year low of $1.70 and a 1 year high of $40.80. The firm has a 50 day moving average of $2.61 and a 200-day moving average of $4.98.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Friday, March 6th. The company reported $3.23 EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.